TuHURA Biosciences Completes Acquisition of Kineta
Provided By PR Newswire
Last update: Jun 30, 2025
Acquisition adds Phase 2 ready novel VISTA inhibiting monoclonal antibody (mAb) to TuHURA's late-stage immuno-oncology pipeline
TuHURA planning to initiate a Phase 2 randomized trial involving VISTA inhibiting antibody in 2nd Half 2025
Read more at prnewswire.com
